Carregant...
The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Hypoxia is an important feature of most solid tumors, conferring resistance to radiation and many forms of chemotherapy. However, it is possible to exploit the presence of tumor hypoxia with hypoxia-activated prodrugs (HAPs), agents that in low oxygen conditions undergo bioreduction to yield cytotox...
Guardat en:
| Publicat a: | Front Pharmacol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8091515/ https://ncbi.nlm.nih.gov/pubmed/33953675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.636892 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|